With 70 partnered development programs, it is a chore to keep tabs on the progress at Ligand Pharma LGND. Continue reading below for a few updates from partner companies disclosed on 3q-2012 earnings conference calls.
Eli Lilly LLY (transcript via Morningstar)
Changes since our last earnings call are highlighted with green arrows showing progression and red arrows showing attrition. You'll see that we began Phase III testing of our once-daily oral CETP inhibitor, Evacetrapib, being studied for the treatment of high-risk vascular disease. Our pivotal trial called ACCELERATE, began earlier this month. It's slated to enroll approximately 11,000 patients and could complete in late 2015
Talk a little bit about the clinical program for your CETP, how you're comparing that to anacetrapib, but I think it's running a very -- can be a bit different Phase III program, and how you see your CETP differentiating from anacetrapib?
In relation to CETP inhibitors, our evacetrapib have shown, as you know, impressive elevation of high-density lipoprotein cholesterol, HDL, and also a lowering of LDL, which you could say is relatively similar to what anacetrapib have been publishing. To directly compare them, though, it's harder to do it since we'd really need head-to-head studies. Both agents have also shown that they don't share the properties of torcetrapib, the Pfizer agent that failed in relation to blood pressure effects. The type of outcome trials that we have for evacetrapib is in 11,000-patient trials and with a MACE outcome that is somewhat different in relation to endpoints compared to Merck's trial. And we also have a higher-risk population for cardiovascular outcomes. We are considering potentially here to publish a design paper together with the study investigators to provide more details about this trial.
Note that I believe this is a Captisol program, but it has not been publicly confirmed by LGND
Merck MRK (transcript via SeekingAlpha)
In addition, we will soon start Phase II trials with our novel base inhibitor, which we are studying for the treatment of Alzheimer's disease.
And secondly, assuming that Phase II is positive, what is the earliest you could move your BACE inhibitor into Phase III, and how soon after that can we see data? This looks like a phenomenal drug, and I'm just wondering when we could look forward to its late-phase development.
We are also excited about BACE. Alzheimer's disease, first of all, is a priority area for Merck, and it's something important for us. We're planning to begin Phase II trials later this year, and we'll be able to provide more details at that time about what the trial will involve. And I just have to say stay tuned, but we share your excitement about this particular compound and the opportunity that we have in terms of Alzheimer's disease.
And then finally, with regards to your Alzheimer's drug, are you planning to evaluate that earlier in earlier-stage patients, such as prodromal patients, considering what we've seen from some of the agents that are a little bit ahead of you?
And with respect to our BACE program, as I said before, we're planning to begin Phase II trials later this year and we'll be able to provide more details at the time the trial begins. But I will reiterate again, we're excited about this program. Alzheimer's disease is a priority area for the company, and the amyloid hypothesis remains a leading approach for disease modification for Alzheimer's disease. MK-8931, it appears, it can reduce cerebrospinal fluid, A beta peptides by greater than 90% in healthy volunteers without dose-limiting side effects. And so we will continue to study this drug as we move forward, and we have a tremendous opportunity to design clinical programs that allow us to exploit it across a variety of patients.
GSK (transcript via SeekingAlpha)
Newer products in our specialty franchise has also continued to perform well... Promacta up 59%
Celgene CELG (transcript via Morningstar)
The recent market introduction of subcutaneous bortezomib and carfilzomib are creating new consideration for our hematologists will treat multiple myeloma. Our research reports that the market use of sub-Q bortezomib is rapidly replacing intravenous bortezomib including in combination used with REVLIMID. Carfilzomib was launched late in the quarter and early market share data suggests single-agent uses third or fourth-line treatment and some combination used with REVLIMID in earlier lines of therapy. In the market and in clinical research, REVLIMID continues to be the foundation of treatment for patients with multiple myeloma. This bodes very well for the product's long-term growth trajectory both in the U.S. and globally
Onyx Pharma ONXX
Extensive discussion about recently launched Kyprolis (carfilzomib) on the earnings call.
Changes since our last earnings call are highlighted with green arrows showing progression and red arrows showing attrition. You'll see that we began Phase III testing of our once-daily oral CETP inhibitor, Evacetrapib, being studied for the treatment of high-risk vascular disease. Our pivotal trial called ACCELERATE, began earlier this month. It's slated to enroll approximately 11,000 patients and could complete in late 2015
Talk a little bit about the clinical program for your CETP, how you're comparing that to anacetrapib, but I think it's running a very -- can be a bit different Phase III program, and how you see your CETP differentiating from anacetrapib?
In relation to CETP inhibitors, our evacetrapib have shown, as you know, impressive elevation of high-density lipoprotein cholesterol, HDL, and also a lowering of LDL, which you could say is relatively similar to what anacetrapib have been publishing. To directly compare them, though, it's harder to do it since we'd really need head-to-head studies. Both agents have also shown that they don't share the properties of torcetrapib, the Pfizer agent that failed in relation to blood pressure effects. The type of outcome trials that we have for evacetrapib is in 11,000-patient trials and with a MACE outcome that is somewhat different in relation to endpoints compared to Merck's trial. And we also have a higher-risk population for cardiovascular outcomes. We are considering potentially here to publish a design paper together with the study investigators to provide more details about this trial.
Note that I believe this is a Captisol program, but it has not been publicly confirmed by LGND
Merck MRK (transcript via SeekingAlpha)
In addition, we will soon start Phase II trials with our novel base inhibitor, which we are studying for the treatment of Alzheimer's disease.
And secondly, assuming that Phase II is positive, what is the earliest you could move your BACE inhibitor into Phase III, and how soon after that can we see data? This looks like a phenomenal drug, and I'm just wondering when we could look forward to its late-phase development.
We are also excited about BACE. Alzheimer's disease, first of all, is a priority area for Merck, and it's something important for us. We're planning to begin Phase II trials later this year, and we'll be able to provide more details at that time about what the trial will involve. And I just have to say stay tuned, but we share your excitement about this particular compound and the opportunity that we have in terms of Alzheimer's disease.
And then finally, with regards to your Alzheimer's drug, are you planning to evaluate that earlier in earlier-stage patients, such as prodromal patients, considering what we've seen from some of the agents that are a little bit ahead of you?
And with respect to our BACE program, as I said before, we're planning to begin Phase II trials later this year and we'll be able to provide more details at the time the trial begins. But I will reiterate again, we're excited about this program. Alzheimer's disease is a priority area for the company, and the amyloid hypothesis remains a leading approach for disease modification for Alzheimer's disease. MK-8931, it appears, it can reduce cerebrospinal fluid, A beta peptides by greater than 90% in healthy volunteers without dose-limiting side effects. And so we will continue to study this drug as we move forward, and we have a tremendous opportunity to design clinical programs that allow us to exploit it across a variety of patients.
GSK (transcript via SeekingAlpha)
Newer products in our specialty franchise has also continued to perform well... Promacta up 59%
Celgene CELG (transcript via Morningstar)
The recent market introduction of subcutaneous bortezomib and carfilzomib are creating new consideration for our hematologists will treat multiple myeloma. Our research reports that the market use of sub-Q bortezomib is rapidly replacing intravenous bortezomib including in combination used with REVLIMID. Carfilzomib was launched late in the quarter and early market share data suggests single-agent uses third or fourth-line treatment and some combination used with REVLIMID in earlier lines of therapy. In the market and in clinical research, REVLIMID continues to be the foundation of treatment for patients with multiple myeloma. This bodes very well for the product's long-term growth trajectory both in the U.S. and globally
Onyx Pharma ONXX
Extensive discussion about recently launched Kyprolis (carfilzomib) on the earnings call.
RSS Feed
